RECRUITING

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Talk to us

Conditions

Obstructive Hypertrophic Cardiomyopathy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Official Title

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

Quick Facts

Study Start:2024-05-10
Study Completion:2027-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06551129

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants ≥18 years of age.
  2. * Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
  3. * Provided informed consent to participate in the study
  1. * Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
  2. * Treated for \>7 days with mavacamten by the day of completing the baseline survey
  3. * Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
  4. * Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
  5. * Had stroke or transient ischemic attack within the six-month period prior to the screening
  6. * Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe
  7. * Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening
  8. * Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay
  9. * Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening

Contacts and Locations

Study Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Analysis Group Inc.
Boston, Massachusetts, 02199
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-10
Study Completion Date2027-06-30

Study Record Updates

Study Start Date2024-05-10
Study Completion Date2027-06-30

Terms related to this study

Keywords Provided by Researchers

  • Obstructive Hypertrophic cardiomyopathy

Additional Relevant MeSH Terms

  • Obstructive Hypertrophic Cardiomyopathy